Project Grant R21HL181690
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$234K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 "Cardiovascular Diseases Research" will provide $126,059 from September 1, 2024 to August 31, 2029 to the University of Colorado-Denver. The project aims to use proteomics and metabolomics approaches to study the systems biology of acute and chronic multi-organ failure in children with congenital heart disease (CHD). Specifically, the project will measure changes in the circulating...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $117,000 to conduct secondary analysis of 3D echocardiography images to compute 3D surface strain of the right ventricle. The goal is to develop computational methods that enable routine spatial and temporal examination of 3D strains using machine learning, and compare these novel 3D strain parameters to disease outcomes in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,588 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant supports the career development of Dr. Son Duong, a clinician-scientist specializing in pediatric cardiology and advanced cardiovascular imaging, into an independent investigator. The primary objectives are to: 1) Develop and validate a prediction tool for right ventricular volumes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,800 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on July 20, 2025, will fund research to predict the hemodynamic response to mitral valve interventions using pressure-volume analysis. The research aims to: 1) identify new echocardiographic measures of left ventricular systolic function in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The research aims to: 1) define the relationship between SCD adverse outcomes and single-cell biochemical/mechanical properties to identify the most promising biomarkers; 2) define the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology to isolate and quantify the contributions of passive and active remodeling events to left ventricular diastolic dysfunction (LVDD). The total award amount is $702,534, with a project period from March 6, 2025 to December 31, 2029. The awardee,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $154,796 to Vanderbilt University Medical Center to utilize non-invasive neuroimaging methods to investigate cerebral oxygen utilization in adults with sickle cell disease (SCD). The research aims to: 1) assess how treatment-induced increases in hemoglobin levels impact cerebral blood flow and arterial-to-venous transit times in SCD...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...